Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Photon Therapy Clear all
Completed Not applicable Interventional

Quality of Life and Supportive Care Preferences Following Radiation Therapy in Prostate Cancer Survivors

NCT02704377
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Undergo HRV and wear accelerometer to assess therapy complications, Dual X-ray Absorptiometry, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 25, 2026, 6:47 PM EDT
Active, not recruiting Phase 3 Interventional

Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer

NCT01893307
View directory record Official record
Conditions
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 25, 2026, 6:47 PM EDT
Not yet recruiting Phase 2 Interventional

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

NCT07466498
View directory record Official record
Conditions
Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection
Drug · Procedure · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 25, 2026, 6:47 PM EDT
Completed Phase 2 Interventional

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

NCT00002634
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, monoclonal antibody 3F8, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, mesna, perfosfamide, vincristine sulfate, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy, radioisotope therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 25, 2026, 6:47 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

NCT00602667
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy, Intermediate-Risk Therapy
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 5 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 25, 2026, 6:47 PM EDT
Completed Phase 3 Interventional

Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

NCT00002875
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, lomustine, mesna, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 22 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
36
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Sep 25, 2026, 6:47 PM EDT
Suspended Phase 1 Interventional

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

NCT06888323
View directory record Official record
Conditions
Refractory Myelodysplastic Syndrome
Interventions
Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab, Computed Tomography, Single Photon Emission Computed Tomography
Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 25, 2026, 6:47 PM EDT
Terminated No phase listed Observational

Photon/Proton Radiation Therapy for Oropharyngeal Cancers

NCT00797446
View directory record Official record
Conditions
Oropharyngeal Cancers
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 25, 2026, 6:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

NCT07213934
View directory record Official record
Conditions
Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Proton therapy, Pembrolizumab
Radiation · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 25, 2026, 6:47 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

NCT06657209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
Interventions
Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone
Procedure · Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 25, 2026, 6:47 PM EDT
Recruiting Phase 2 Interventional

A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma

NCT06485778
View directory record Official record
Conditions
Oral Tongue Squamous Cell Carcinoma
Interventions
Photon intensity modulated radiation therapy (IMRT), Life questionnaire's
Radiation · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 25, 2026, 6:47 PM EDT
Terminated Phase 2 Interventional Results available

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

NCT04364048
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Carcinoma
Interventions
Induction Durvalumab, Chemotherapy, Radiation, Consolidation durvalumab
Drug · Radiation
Lead sponsor
Rachel Sanborn
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Wichita, Kansas • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 25, 2026, 6:47 PM EDT
Completed Not applicable Interventional

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

NCT02592356
View directory record Official record
Conditions
Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Thyroid Gland Medullary Carcinoma
Interventions
Computed Tomography, Dual X-ray Absorptiometry, Physical Examination, Quality-of-Life Assessment, Questionnaire Administration, Cabozantinib, Lenvatinib
Procedure · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 25, 2026, 6:47 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus

NCT00002631
View directory record Official record
Conditions
Esophageal Cancer
Interventions
chemotherapy, cisplatin, fluorouracil, low-LET electron therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
17
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 25, 2026, 6:47 PM EDT
Recruiting Phase 2 Interventional

Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

NCT03215719
View directory record Official record
Conditions
Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Standard Radiation Treatment, Dose-Deescalated Treatment, Cisplatinum
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 25, 2026, 6:47 PM EDT
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 25, 2026, 6:47 PM EDT
Completed Phase 2 Interventional

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00002774
View directory record Official record
Conditions
Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)
Interventions
Tirapazamine, Cisplatin, 5-fluorouracil, Radiotherapy (RT)
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
17 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 25, 2026, 6:47 PM EDT
Completed Phase 2 Interventional

Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer

NCT00002889
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, goserelin, leuprolide acetate, low-LET photon therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
30 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 25, 2026, 6:47 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome

NCT00514501
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Iodofiltic acid I 123
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
40 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Sep 25, 2026, 6:47 PM EDT
Recruiting No phase listed Observational

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

NCT06389097
View directory record Official record
Conditions
Prostate Cancer, Advanced Cancer
Interventions
Radium-223, 177Lu-DOTATATE, 177Lu-PSMA-617
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 25, 2026, 6:47 PM EDT
Recruiting Phase 2 Interventional

GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries

NCT07415681
View directory record Official record
Conditions
Gynaecologic Cancer, Cervical Cancer, Radiation Therapy
Interventions
Volume Modulated Arc Therapy (VMAT), Intensity Modulated Proton Therapy (IMPT)
Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
5
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 25, 2026, 6:47 PM EDT
Recruiting Not applicable Interventional

Low-Count Quantitative SPECT for Men Treated With Radium-223

NCT07221825
View directory record Official record
Conditions
Prostate Cancer, Cancer of the Prostate
Interventions
Low-count quantitative single-photon emission computed tomography imaging
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 25, 2026, 6:47 PM EDT
Recruiting Not applicable Interventional

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

NCT07555210
View directory record Official record
Conditions
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer, MSI-H/dMMR Rectal Cancer, Squamous Cell Carcinoma Mouth, Invasive Mammary Carcinoma, Classic Hodgkin Lymphoma
Interventions
Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
Device
Lead sponsor
Jessica Mezzanotte Sharpe
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 6:47 PM EDT
Active, not recruiting Not applicable Interventional

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

NCT03896646
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Computed Tomography, Hepatobiliary Iminodiacetic Acid Scan, Single Photon Emission Computed Tomography, Yttrium Y 90 Glass Microspheres, Yttrium-90 Microsphere Radioembolization
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 6:47 PM EDT